Britain's GSK and China's Jiangsu Hengrui Pharmaceuticals have agreed on a $500 million deal to develop up to a dozen new ...

Having recently scored approval for Nucala in chronic obstructive pulmonary disease (COPD), GSK has now signed a major ...

GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...

The deal, which focuses first on a COPD drug GSK believes holds “best-in-class” potential, could involve a dozen medicines ...

China's Jiangsu Hengrui Pharmaceuticals said on Monday it has agreed to license the global rights of its HRS-9821 drug and 11 other programmes to GlaxoSmithKline Intellectual Property (GSK) for $500 ...

GSK is paying $500M upfront for rights to a series of Hengrui drugs, the latest case of a pharma company looking to a Chinese ...

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 billion.

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and inflammation.

Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several ...

Hengrui Pharma delivered a strong international presence, featuring 15 innovative drugs and 72 research outcomes. These included 4 oral presentations, 5 rapid oral presentations, 27 poster ...

Jiangsu Hengrui Pharmaceuticals Co. has started taking investor orders for a Hong Kong listing that could raise as much as HK$9.9 billion ($1.3 billion), the latest significant deal to boost the ...

A Hengrui drug that interferes with a cancer cell’s DNA damage response is heading to Merck KGaA for €160 million up front and up to €1.4 billion tied to milestones.